Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2017-07-19
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells
and either kill them or deliver cancer-killing substances to them without harming normal
cells. It is not yet known whether chemotherapy is more effective with or without rituximab
for relapsed non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying combination chemotherapy and rituximab
to see how well they work compared to combination chemotherapy alone in treating patients
with relapsed non-Hodgkin's lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
Australasian Leukaemia and Lymphoma Group Lymphoma Trials Office NCIC Clinical Trials Group Nordic Lymphoma Group Stichting Hemato-Oncologie voor Volwassenen Nederland